Inductal

Quick links to important sections

Inductal

Method of action: Hypnotic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Inductal

What is Inductal? Overview and Quick Facts

Inductal is a prescription-only synthetic medicine, specifically classified as a Nonbenzodiazepine hypnotic agent, designed to help regulate the sleep-wake cycle. The active substance, Eszopiclone, is utilized in the management of sleep disorders.

Property Description
Active ingredient Eszopiclone
Form Film-coated tablet
Pharmacological class Hypnotic (Nonbenzodiazepine)
General purpose Sleep disorder management
Origin Synthetic (S-enantiomer)

Inductal: Classification and Definition of the Hypnotic Agent

Inductal is grouped informally as a Z-drug, a classification that sets it apart from older, chemically broader sedative medications. Its chemical structure is a cyclopyrrolone derivative. Eszopiclone is classified as a controlled substance due to its potential for dependence, underscoring its status as a strictly managed pharmaceutical intervention.

The active ingredient is the pure S-enantiomer of its parent compound, Zopiclone. This single-enantiomer structure is a key differentiating feature in its composition, as it provides the primary therapeutic effect necessary for achieving sedation induction in adults.


Composition and Pharmacologic Function

The medication is prepared for use as an oral dosage form in a stable film-coated tablet. It is a single-ingredient product, containing only the Eszopiclone active substance alongside its solid excipient matrix. This oral format provides a conventional and manageable route for delivery.

The drug's function is rooted in its role as a positive allosteric modulator of the GABAA receptor complex. By enhancing the effect of the brain's main inhibitory neurotransmitter, GABA, Inductal effectively reduces general nerve excitability across the central nervous system. This CNS depressant action ultimately allows for both a faster sleep onset and more consistent sleep maintenance regulation.

What side effects are possible with Inductal?

Possible side effects and safety information

The safety profile of Inductal (Eszopiclone) is organized based on how adverse reactions are classified and documented by government regulatory agencies. The occurrence of side effects is formally categorized by frequency, allowing for the communication of risks observed during clinical use.

Adverse Reactions by Frequency and System

The most frequently reported adverse reaction documented in regulatory labels is dysgeusia, which is defined as an unpleasant taste. Other common effects reflecting the medication's intended action on the central nervous system include somnolence (drowsiness) and dizziness, as well as headache and dry mouth. Reactions classified as uncommon or rare in official documents include episodes of hallucinations, anxiety, and symptoms related to the gastrointestinal system.

System-Organ Class Common Adverse Reactions
Nervous System Disorders Somnolence, Dizziness, Headache
Gastrointestinal Disorders Dysgeusia, Dry Mouth

Serious Adverse Reactions and Safety Constraints

The official labeling specifies certain serious risks, most notably the occurrence of complex sleep behaviors. These involve activities such as sleep-driving, making phone calls, or preparing food while not fully awake, often followed by amnesia for the event. This risk is a key safety constraint. Inductal is classified as a Controlled Substance (Schedule IV) by the FDA due to the potential for the development of physical and psychological dependence, a risk which increases with the duration of use.

Population-Specific Considerations

Safety statements address increased risk for specific patient groups. Older adults may have increased sensitivity to the medication's effects, leading to a heightened risk of impaired motor and cognitive performance. Furthermore, use is a regulatory constraint for individuals with severe hepatic impairment due to the potential for significantly reduced drug clearance. The regulatory documentation also notes the potential for residual sedation to persist into the day after use, particularly if less than a full 7 to 8 hours of sleep is achieved.

Overdose and Emergency Response

Overdose and When to Seek Help

Inductal (Eszopiclone) overdose information is based strictly on the drug's official regulatory documentation. Overdose manifestations are documented as an exaggeration of the drug's central nervous system (CNS) depressant effects, and the risk of severe outcomes is heightened when the medicine is combined with other CNS depressants, including alcohol.

Official Overdose Manifestations and Actions

Overdose Domain Regulatory Statement
Documented Presentation Manifests as somnolence, drowsiness, confusion, ataxia, and impaired consciousness.
Severe Outcomes Progression can lead to respiratory depression, hypotension, coma, and death.
Immediate Action Required Individuals must seek immediate medical attention or contact a Poison Control Center for any suspected overdose.
Antidote Flumazenil may be considered, but it is not the specific antidote and may carry an increased risk of seizures.

Management and Monitoring

Management of overexposure requires general symptomatic and supportive treatment. Medical personnel must employ continuous cardiovascular and respiratory monitoring due to the potential for severe systemic outcomes. Procedures such as immediate gastric lavage and administration of activated charcoal may be utilized as part of the management strategy. The possibility of multiple drug ingestion must always be considered when evaluating these scenarios.

Therapeutic Uses of Inductal

What Inductal Treats: Main Uses and Benefits

Inductal (Eszopiclone) is commonly used across domains where additional symptomatic support is needed for the management of insomnia, a condition where functional stability may become affected by poor sleep. The medication is relevant for easing symptoms that interfere with daily comfort in patients who experience difficulty falling asleep as well as those who struggle with sleep maintenance throughout the night.

The medication is applied in addressing the symptom clusters of insomnia related to both sleep initiation (difficulty falling asleep) and sleep maintenance (frequent nighttime awakenings).

“By easing the overall symptom load of nighttime distress, the medication supports general well-being during symptomatic phases.”

This medication may be considered relevant for both transient (short-term) and chronic (long-term) forms of the disorder. Inductal plays a role in managing these symptoms by assisting with a decrease in sleep latency and may assist with maintaining sleep continuity. This provides supportive relief when symptoms interfere with routine activities, particularly for adult patients. The overall therapeutic goal is to contribute to improved comfort during periods of sleep loss and may assist with total sleep time.


Key Use: Addressing Fragmented Sleep Symptoms The medication is commonly used to help with a decrease in wake time after sleep onset (WASO), which is the time spent awake during the night after the initial sleep period, which supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

The official regulatory profile for Inductal (Eszopiclone) defines strict criteria for patient eligibility. Use is primarily established for adult patients (ages 18 and older) managing insomnia.

Populations Who Must Not Use Inductal

The medicine is contraindicated in specific groups, as defined by regulatory labeling:

  • Patients with a known hypersensitivity or severe allergic reaction to eszopiclone or any component of the medication.
  • Patients who have previously experienced complex sleep behaviors (such as sleep-driving or engaging in activities while not fully awake) after taking Inductal or a similar sedative-hypnotic.

Restricted and Conditional Use

Use is permitted but regulated for several populations:

  • Older Adults (65 and over): Eligibility is conditional, with a lower maximum dosage limit defined by regulatory bodies due to increased sensitivity.
  • Severe Hepatic Impairment: Patients with severe liver disease require a reduced maximum dose due to the body's decreased ability to process the drug. No dose adjustment is typically needed for renal impairment.
  • Pediatric Patients: Safety and effectiveness have not been established for use in individuals under the age of 18.
  • Pregnancy and Lactation: Use during pregnancy is restricted and recommended only if the potential benefit justifies the potential risk. Use during lactation is generally not recommended.
  • Controlled Substance Status: The drug's classification as a controlled substance mandates careful surveillance for patients with a history of alcohol or substance abuse.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Inductal (Eszopiclone) is documented by regulatory authorities based on two primary mechanisms: drug metabolism and central nervous system (CNS) effects. All factual interaction statements are based on official government labeling.

Interactions Affecting Drug Exposure (Pharmacokinetic)

Eszopiclone is primarily metabolized by the hepatic enzymes CYP3A4 and CYP2E1. The co-administration of potent CYP3A4 inhibitors, such as Ketoconazole, is documented to significantly increase Eszopiclone exposure, with one study reporting an increase of approximately 2.2-fold in plasma concentration. Conversely, the use of CYP enzyme inducers, like Rifampicin, is expected to decrease Eszopiclone exposure and potentially reduce its overall effect. This exposure alteration necessitates regulatory constraints.

Interactions Affecting CNS Function (Pharmacodynamic)

Concomitant use with other CNS depressants results in an officially documented additive CNS-depressant effect. This includes medicinal products such as opioids, benzodiazepines, tricyclic antidepressants, and antipsychotics. Use with alcohol (Ethanol) is strictly cautioned against due to the additive effect on psychomotor performance.

Administrative and Population Restrictions

Timing-based interaction rules specify that the medication must not be taken with or immediately after a high-fat meal, as this affects absorption and may reduce the documented effect on sleep onset. Furthermore, population-specific interaction notes indicate that exposure is increased approximately 2-fold in patients with severe hepatic impairment. Due to the combination of metabolic factors and population sensitivity, co-administration with a potent CYP3A4 inhibitor is formally contraindicated in elderly patients.

Mechanism of Action

Targeted Receptor and Enzyme Modulation

Inductal acts by highly selective modulation of specific receptor and enzyme systems, which are key regulatory components in cellular signaling. This precise interaction initiates the mechanistic cascade through site-specific binding and allosteric changes.

Signal Transduction and Pathway Dampening

The drug’s primary action involves operating within defined signal transduction cascades to dampen overactive signaling. By modifying the early molecular steps, Inductal acts to limit the amplification of excessive activity within the targeted neural or humoral pathways, specifically by altering the phosphorylation status of intracellular effectors.

Regulation of Central and Peripheral Systems

This mechanistic influence contributes to the regulation of central and/or peripheral systems where specific mediators dominate. This pathway adjustment results in a modulated state within targeted regulatory systems, which shapes the resulting non-therapeutic physiological response.

Dosage and Administration Information

Administration Scope

Inductal is a film-coated tablet administered via the oral route, available in strengths of 1 mg, 2 mg, and 3 mg. The standardized regimen is centered on the time and context of ingestion. The recommended initial dose for non-elderly adults is 1 mg once daily, taken immediately before bedtime. Dosing may be increased up to a maximum of 3 mg if clinically indicated.

The medicine must be taken on an empty stomach; concurrent administration with a heavy, high-fat meal should be avoided as this delays absorption. Crucially, the dose should only be taken when the individual can commit to 7 to 8 hours of sleep time before the planned time of awakening.

Dose Adjustments and Procedural Rules

Specific maximum doses apply to certain populations. For older adults (aged 65 years and older) or those with severe hepatic impairment, the total daily dose should not exceed 2 mg. No dose adjustment is generally necessary for patients with renal impairment. The tablet must be swallowed whole and should not be crushed or broken.

If a daily dose is missed, it should be skipped entirely, and administration should resume with the next scheduled dose; doses must never be doubled. If the use pattern does not lead to improvement after 7 to 10 days of treatment, the overall therapeutic course warrants reevaluation.

Recent Clinical Evidence

Research Evidence Overview for Inductal (Eszopiclone)

This section summarizes the official clinical research and scientific reviews that was studied for Inductal, focusing on the types of trials conducted and the specific endpoints research examined in relation to its approved uses. The evidence contributes to understanding symptom patterns, but findings describe group patterns, not personal outcomes.

Evidence for Primary Insomnia: Sleep Initiation and Maintenance

The foundational research for Inductal primarily consists of placebo-controlled trials (RCTs). These studies were evaluated in populations of adults diagnosed with primary insomnia. Researchers utilized advanced sleep measurements in laboratory settings (Polysomnography) to monitor objective sleep measures, objectively measuring things like the time needed to fall asleep (Sleep Latency) and the time spent awake during the night (WASO). The findings describe patterns observed in the studies where reported outcomes included measurements of Sleep Latency in both objective and subjective assessments, in the context of placebo control. Evidence from longer-term trials studies report how symptoms evolved over several months of observation, exploring extended-duration data in patients with chronic symptoms.

Research in Insomnia Co-occurring with Other Conditions

Specific research was studied for Inductal in populations with insomnia co-occurring with other medical conditions. This included dedicated Randomized Controlled Trials and smaller Pilot Studies focusing on populations such as adults with insomnia linked to conditions such as rheumatoid arthritis and stroke recovery. In these trials, research examined standard sleep outcomes alongside outcomes related to systemic or functional imbalance, such as pain scales and measures of physical functioning. However, this evidence is limited, as reported outcomes were based on smaller patient groups and often utilized short-term observation periods.

Research Gaps and Areas of Uncertainty

Certainty remains low in several areas, as research is ongoing. There is limited information for long-term outcomes available, and follow-up durations were limited in specific patient groups. Data for certain groups remain insufficient, particularly for the oldest segment of the population (those aged 75 years and older). Furthermore, comparative evidence is lacking for large-scale, head-to-head trials against all other contemporary hypnotic medications. The evidence highlights what is known—and what is still uncertain—and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Inductal (FAQ)


Q: How quickly does Inductal start working after I take it?

Official studies indicate that Inductal can facilitate the start of sleep, consistent with its approval for insomnia.


Q: How long do the effects of Inductal last?

The effect of the active substance in Inductal is associated with a half-life of approximately 6 hours, according to official pharmacological data. Safety information notes the potential for residual drowsiness or sedation to persist into the following day, particularly if less than a full 7 to 8 hours of rest is obtained.


Q: Can I take Inductal if I'm already taking supplements like fish oil or multivitamins?

Official interaction data focuses on prescription medications that affect liver enzymes; regulatory documents do not specify whether common dietary supplements, such as fish oil or multivitamins, significantly alter Inductal’s effects.


Q: Can Inductal cause stomach upset or nausea?

Official regulatory labels include reports of gastrointestinal symptoms in adverse reaction data. Nausea has been observed in clinical trials.


Q: Does the effectiveness of Inductal change over time?

Regulatory documents state that if a patient's insomnia does not show improvement after 7 to 10 days of treatment, the therapeutic course warrants reevaluation. Furthermore, clinical studies have examined the medicine's effect over several months, with research findings reporting that observed effects on sleep measures were maintained in the studied populations.


Q: Is a metallic taste in the mouth a common side effect of Inductal?

Regulatory labels state that the most frequently reported adverse reaction is dysgeusia (an altered or unpleasant taste). This is often described by users as a metallic or bitter taste.


Q: Do I need to take Inductal with food?

The official labeling indicates that Inductal should be taken on an empty stomach. Use with a heavy, high-fat meal is noted to interfere with the medicine's absorption and delay its expected action.


Q: Can Inductal cause weight gain or weight loss?

Official adverse reaction listings report both increases and decreases in body weight, though these effects are classified as uncommon or rare.


Q: Is it normal to feel slightly dizzy after starting Inductal?

Official regulatory labels classify dizziness as a common adverse reaction observed in clinical trials. This finding is consistent with the known central nervous system activity of this type of medicine.


Q: How is Inductal different from other medicines used for the same purpose?

Inductal is chemically defined as a Nonbenzodiazepine hypnotic agent, sometimes informally referred to as a Z-drug. Official pharmacological information notes that its active substance is the pure S-enantiomer of its parent compound, which is a key component of its specific action.


Q: Does Inductal affect sleep patterns or cause insomnia?

Although the drug is intended to treat insomnia, official adverse reaction data reports that rare cases of insomnia have been observed in clinical trials. This indicates that a paradoxical effect, though uncommon, has been documented.


Q: Can Inductal cause mood swings or changes in emotional state?

Adverse reactions related to mental state are documented in the official safety profile. These include reports of anxiety and hallucinations, though these types of effects are typically classified as uncommon or rare.


Q: Is Inductal addictive or habit-forming?

Inductal is formally classified as a Controlled Substance (Schedule IV) by the FDA. The classification as a Controlled Substance is due to the potential for the development of physical and psychological dependence, which is a risk noted to increase with the duration of use.


Q: Is Inductal usually taken once a day or multiple times?

Official prescribing information indicates that the standardized regimen for Inductal is centered on administration once daily.


Q: Can I drive or operate machinery while taking Inductal?

Official safety warnings advise patients that the medicine can potentially cause impaired motor and cognitive performance. Patients are cautioned against operating dangerous machinery or driving until they are certain the medication does not cause next-day drowsiness or impairment.


Q: Will Inductal interfere with birth control pills?

Official drug interaction data focuses on medications that affect certain liver enzymes (CYP3A4 and CYP2E1). Regulatory documents do not specifically indicate a significant interaction between Inductal and common oral contraceptives.


Q: Why do some people stop taking Inductal?

Reasons for discontinuation, as suggested by regulatory constraints and safety data, include experiencing specific serious adverse reactions, such as complex sleep behaviors, or experiencing common, unpleasant side effects like the altered taste (dysgeusia). Lack of clinical improvement after a short course of treatment may also lead to reevaluation.


Q: Is Inductal a long-term treatment or a short-term one?

Inductal is approved for the treatment of insomnia. Clinical research supporting its use has included both short-term evaluations and extended-duration trials of up to six months, with efficacy and safety information available for both contexts.


Q: Is it possible to be allergic to Inductal?

Yes. Inductal is formally contraindicated (must not be used) in patients with a known severe allergic reaction or hypersensitivity to the active substance or any of the inactive ingredients.


Q: What should I look out for as an indication that Inductal is working?

Clinical trials measured objective sleep parameters to assess the medicine’s action. Observed effects included a reduction in the time required to fall asleep (Sleep Latency) and less time spent awake after initially falling asleep (WASO).


Q: Is Inductal used to treat chronic pain?

No. Inductal is officially indicated only for the treatment of insomnia. The regulatory indication does not include the treatment or management of chronic pain.

How should Inductal be stored and disposed of?

The storage and disposal of Inductal (Eszopiclone) must adhere strictly to regulatory requirements to ensure product integrity and safety.

Official Storage Conditions

Inductal tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from moisture and excessive heat.

To preserve its stability, keep the medicine in its original container with the lid tightly closed and the desiccant intact.

Handling and Disposal

It is mandatory to keep Inductal out of the reach of children.

As a Controlled Substance, disposal must follow official regulated procedures, such as a drug take-back program. Do not dispose of unused or expired tablets by flushing them down a toilet or pouring them into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Inductal found in:

A-Z Index: